Aquestive Therapeutics

AQST · NASDAQ · Pharmaceutical Preparations

Aquestive Therapeutics (AQST) · oqro.io/stocks/AQST · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.

How this filing works

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Want the short version?

Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.

Explain this page What did insiders at AQST buy and sell in the last 90 days?Which members of Congress and which funds traded AQST recently?

Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.

Insider trades around earnings

2 open-market purchases and 1 open-market sale by insiders of AQST between Feb 2, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 3, 2026. The data provider lists the next release for Mar 2, 2027; that date may change.

PurchaseSale30 days before a release30 days after

Trades in the 30 days around each of the last earnings releases
Earnings release	30 days before	On the day	30 days after
Nov 3, 2026	1 sale	None	2 purchases
Aug 11, 2026	None	None	None
May 13, 2026	None	None	None
Mar 4, 2026	None	None	None

Richard J Daly, Director, Nov 10, 2026, about $95K. Bought 7 days after the company's previous earnings release on 2026-11-03Form 4
Richard J Daly, Director, Nov 10, 2026, about $4.2K. Bought 7 days after the company's previous earnings release on 2026-11-03Form 4
Daniel Barber, President and CEO, Oct 15, 2026, about $106K. Sold 19 days before the company's next earnings release on 2026-11-03Form 4

Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies

Insider trades · 13

Including 3 routine filings (option exercises, tax withholding, grants, gifts). Open-market trades only

Richard J DalyDirector

Filed 2d ago

Bought

~$99Kacross 2 transactionsin 1 filing

Traded Nov 10, 2026 · largest single transaction ~$95K

Show all 2 transactions

Nov 10, 2026~$95K · 27K sh @ $3.55
Details Official record
Nov 10, 2026~$4.2K · 1,200 sh @ $3.53
Details Official record

Matthew W Davis (Officer) plans to sell ~$26K of Aquestive Therapeutics

Planned, from payFiled 2d ago

Insider filing

Matthew W. DavisChief Development Officer

Filed 2d ago

5,303Shares · @ $3.52

Traded Nov 10 · filed 2 days later

Routine share withholding; mechanical by default.

More Official record

Insider filing

Richard J DalyDirector

Filed 4d ago

57KDerivative units

Traded Nov 6 · filed 4 days later

Compensation award — excluded from discretionary-purchase analysis.

More Official record

Insider filing

John CochranDirector

Filed 3w ago

62KShares

Traded Oct 21 · filed 2 days later

Not classified as an open-market trade.

More Official record

Daniel Barber (President and CEO) sold ~$106K of Aquestive Therapeutics

Planned saleFiled 4w ago

Daniel Barber (President and CEO) sold ~$551K of Aquestive Therapeutics

Planned saleFiled 1y ago

Peter E. Boyd (See Remarks) sold ~$63K of Aquestive Therapeutics

Planned saleFiled 1y ago

Daniel Barber (President and CEO) sold ~$2.4K of Aquestive Therapeutics

Planned saleFiled 1y ago

Cassie Jung (Chief Operating Officer) sold ~$311K of Aquestive Therapeutics

Planned saleFiled 1y ago

Peter E. Boyd (See Remarks) sold ~$80K of Aquestive Therapeutics

Planned saleFiled 1y ago

Insider selling

Cassie JungChief Operating Officer

Filed 2y ago

Sold

~$21444 sh @ $4.87

Traded Nov 26, 2024 · filed 1 day laterNot reported under a pre-arranged trading plan

Aquestive Therapeutics's Chief Operating Officer sold $214 of Aquestive Therapeutics shares. The filing does not indicate a pre-arranged trading plan.